Claims
- 1. A method for inhibiting T cell proliferation,said method comprising administering a therapeutically effective amount of a chemical compound having selective IKCa modulatory activity to said mammal, wherein the chemical compound is a triaryl methane derivative represented by Formula VIII or a pharmaceutically acceptable salt or an oxide or a hydrate thereof, whereinn is 0; Ar1 represents a phenyl, furanyl, imidazolyl, oxazolyl, piperidyl, pyridyl, pyrimidinyl, pyrrolyl, thiazolyl or thienyl group, which group may optionally be substituted one or more times with substituents selected from the group consisting of halogen, trihalogenmethyl, alkyl, cycloalkyl, amino, nitro and cyano; and R represents —OR′, —C(O)R′, —C(O)OR′, —C(O)NR′2 or —CH2OR′, wherein R′ represents hydrogen, alkyl or cycloalkyl.
- 2. The method according to claim 1, wherein the compound is (4-chlorophenyl-diphenyl)-carbinol; Ethyl 2-phenyl-2-(1-piperidyl)-phenylacetate; or 1,1,1-triphenylacetone; or a pharmaceutically acceptable salt or an oxide or a hydrate thereof.
- 3. The method according to claim 1, said method further comprising administering a pharmaceutically effective amount of a conventional immune suppressing agent to said mammal.
- 4. The method according to claim 3, wherein the immune-suppressing agent is Amphotericin, Busulphan, Co-trimoxazole, Chlorambucil, colony stimulating factors, corticosteroids, Cyclophosphamide, Fluconazole, folinic acid, Ganciclovir, antilymphocyte immunoglobulins, normal immunoglobulins, Methotrexate, Methylprednisolone, Octreotide, Oxpentifylline, Tacrolimus (FK506), Thalidomide, Zolimomab aritox, or the calcineurin inhibitors (protein phosphatase 2B inhibitors).
- 5. The method according to claim 3, wherein the conventional immune-suppressing agent is Cyclosporin.
- 6. The method according to claim 2, wherein said compound is (4-chlorophenyl-diphenyl)-carbinol.
Priority Claims (1)
Number |
Date |
Country |
Kind |
1999 00659 |
May 1999 |
DK |
|
Parent Case Info
This application is a Continuation-In-Part of PCT International Application No. PCT/DK00/00253 filed on May 12, 2000, which was published in English and which designated the United States and on which priority is claimed under 35 U.S.C. § 120, the entire contents of which are hereby incorporated by reference.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
4996193 |
Hewitt et al. |
Feb 1991 |
A |
5512591 |
Halperin et al. |
Apr 1996 |
A |
5540931 |
Hewitt et al. |
Jul 1996 |
A |
5591763 |
Halperin et al. |
Jan 1997 |
A |
5643936 |
Halperin et al. |
Jul 1997 |
A |
6028103 |
Brugnara et al. |
Feb 2000 |
A |
Foreign Referenced Citations (4)
Number |
Date |
Country |
WO 9418967 |
Sep 1994 |
WO |
WO 9601107 |
Jan 1996 |
WO |
WO 9734589 |
Sep 1997 |
WO |
WO 9925347 |
May 1999 |
WO |
Non-Patent Literature Citations (2)
Entry |
Verheugen et al., Cell Calcium, vol. 21, No. 1, pp. 1-17 (1997). |
Rader et al., The Journal of Immunology, vol. 156, pp. 1425-1430 (1996). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/DK00/00253 |
May 2000 |
US |
Child |
09/986725 |
|
US |